Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Norway / NCT06139770
Active, not recruiting Not applicable

Treatment of Anorexia Nervosa in Children and Adolescents: An Integrated Family Based and Metacognitive Approach

NCT06139770 · tracked via the Priya Life Science Norway tracker
Sponsor
Norwegian University of Science and Technology
Phase
Not applicable
Started
2023-11-01
Last updated
2025-06-22

Condition(s) studied

Anorexia Nervosa

Investigational drug(s) / intervention(s)

Family based therapy- Metacognitive therapy

Family based therapy- Metacognitive therapy: Family based therapy and Metacognitive therapy

Study summary

The goal of this study is to evaluate the treatment effects of an integrated treatment called Family-based and Metacognitive therapy for patients with Anorexia Nervosa. In addition, we will evaluate if an active follow-up of the patients will reduce the number of relapses, which is common during the 1 year after discharge. Fifty patients aged 12-18 years old and their parents will be invited to participate in this study and all will receive the same treatment but be randomly allocated to different follow-up conditions. The active follow-up includes 3 sessions of Metacognitive therapy and the passive follow-up includes ordinary follow-up, with no booster sessions. The patients will be assessed at baseline, pre-treatment, post-treatment, and at 6 and 12 months follow-up.

Eligibility

Sex
ALL
Min age
12 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Primary diagnosis of F 50.0 and F 50.1 Exclusion Criteria: * Psychotic symptoms * Severe somatic illness * Mental retardation or developmental disorder * Bipolar disorder * Extreme self-mutilation or acute suicidal risks * Does not speak or understand Norwegian

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
St.Olavs hospital HF Trondheim Trøndelag

More Norwegian University of Science and Technology trials in Norway

MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway Active, not recruiting
Goal Management Training for Adult Survivors of Childhood Leukemia and Non-Hodgkins Lymphoma With Neurocognitive Sequelae Active, not recruiting
Multimodal Assesment of Alzheimer Patients Recruiting
Bariatric Surgery and Pharmacokinetics of Quetiapine Recruiting
Bariatric Surgery and Pharmacokinetics of Escitalopram Recruiting

Other trials for the same condition

Effectiveness Trial of Temperament Based Therapy With Support (TBT-S) Recruiting
Norwegian Microbiota Study in Anorexia Nervosa Recruiting
Cognitive Training for Patients With Eating Disorders Active, not recruiting
Reestablishing Normal Gut-brain Interaction in Anorexia Nervose With Normal Gut Microbiota Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06139770 on ClinicalTrials.gov ↗ ← All trials in Norway